GPS2 and metabolic dysfunction-associated steatotic liver disease: To determine the clinical relevance of GPS2 in human disease progression, we compared gene expression levels in both NASH (Fig. 6 and Supplementary Fig. 6e–j) and NAFLD (Fig. 6 and Supplementary Fig. 6e–j) human subjects from published transcriptome datasets (GSE83452 and GSE49541)15,16.